NCPA opposes FDA's proposed opioid mail-back program

NCPA June 22, 2022

NCPA submitted comments to FDA on its proposed program regarding mail-back envelopes and education on safe disposal with opioid analgesics. In its comments, to minimize burden on pharmacies, to avoid redundancies with existing programs, and to address its various concerns, NCPA asked FDA to not move forward with the proposals, or at the very least make them part of a strictly voluntary program. NCPA also advocated for any program implemented to be accompanied by compensation for pharmacies, and that any waste/unused medication should not go back to pharmacies. Lastly, NCPA asked FDA to advise CMS to formally recognize pharmacists as providers eligible to furnish those opioid abuse reduction services in their scope of practice and claim reimbursement under Medicare Part B.